Egyptian healthtech startup 30Med has announced securing pre-seed funding from undisclosed angel investors, marking a significant milestone in its journey to revolutionize medical education. The funding round is expected to provide 30Med with the necessary resources to enhance its platform and broaden its reach within the medical community.

Founded in 2023 by Ayman Ragab, 30Med operates in the business-to-business (B2B) space, with a primary objective of bridging the gap between pharmaceutical companies and physicians. The startup has gained recognition for its innovative approach, leveraging interactive videos and conference events to showcase new medicines and facilitate continuous learning for medical professionals.

With a user base exceeding 2,000 actively engaged doctors, 30Med has established itself as a prominent player in the field, offering a platform for physicians to stay updated on the latest advancements in medicine and pharmaceuticals. Dr. Ayman Ragab, CEO of 30Med, expressed enthusiasm about the funding, stating, “This funding is a strong validation of our mission. It allows us to accelerate our efforts in transforming medical education.”

30Med’s success can be attributed to its strategic partnerships with pharmaceutical companies in Egypt. These partnerships underscore the startup’s commitment to reshaping the medical education landscape within the country. By facilitating collaboration between healthcare providers and pharmaceutical firms, 30Med aims to drive innovation and improve patient care standards.

The pre-seed funding represents a vote of confidence from investors in 30Med’s vision and potential impact on the healthcare sector. As the startup continues to evolve and expand its offerings, it is poised to play a significant role in shaping the future of medical education in Egypt and beyond.